On September 7, 2021 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer reported that it will present at upcoming investor conferences (Press release, Panbela Therapeutics, SEP 7, 2021, View Source;utm_medium=rss&utm_campaign=panbela-to-present-at-upcoming-investor-conferences [SID1234587284]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021
Presentation will be available on-demand beginning September 13, 2021
Webcast: View Source
Management will also host 1×1 investor meetings during the conference.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23
Presentation Date and Time: September 21, 2021, at 9:55am ET
Event link: View Source
Management will also host 1×1 investor meetings during the conference.
To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Recently observed serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit View Source